Curtis Tyree

Corporate Officer/Principal en ORGANOVO HOLDINGS, INC. .

Health Technology

Perfil

Curtis Tyree is currently the Senior VP-Strategy & Business Development at Organovo Holdings, Inc. He previously worked as the Senior Vice President-Strategic Planning at HUYA Bioscience International LLC.

Cargos activos de Curtis Tyree

Empresas	Cargo	Inicio
ORGANOVO HOLDINGS, INC.	Corporate Officer/Principal	18/02/2022

Todos los cargos activos de Curtis Tyree

Antiguos cargos conocidos de Curtis Tyree.

Empresas	Cargo	Fin
HUYA Bioscience International LLC HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA.	Corporate Officer/Principal	-

Ver el detalle de la experiencia de Curtis Tyree.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Curtis Tyree.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	1
ORGANOVO HOLDINGS, INC.	Health Technology

Empresas privadas	1
HUYA Bioscience International LLC HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA.	Health Technology